Table 2 Description of the baseline characteristics of the patients in the different studies included in the meta-analysis
Faglia et al. (2005) | DIAD (2009) | DYNAMIT (2011) | FACTOR-64 (2014) | DADDY-D (2015) | |
|---|---|---|---|---|---|
Number of patients | |||||
- Screening | 71 | 561 | 316 | 452 | 262 |
- Control | 70 | 562 | 315 | 447 | 258 |
Age, y ± SD | |||||
- Screening | 58.7 ± 8.3 | 60.7 ± 6.7 | 64.1 ± 6.4 | 61.5 ± 7.9 | 61.9 ± 4.8 |
- Control | 61.5 ± 8.1 | 60.8 ± 6.4 | 63.7 ± 6.4 | 61.6 ± 8.4 | 62.0 ± 5.1 |
BMI, kg/m2 ± SD | |||||
- Screening | 27.2 ± 5.1 | 31.1 ± 6.5 | 30.4 + 4.7 | 32.9 ± 6.8 | 29.6 ± 4.9 |
- Control | 28.3 ± 4.6 | 31.0 + 6.1 | 30.8 ± 5.3 | 33.4 ± 7.1 | 30.6 ± 7.2 |
Women | |||||
- Screening | 39 % | 48 % | 45 % | 48 % | 20 % |
- Control | 47 % | 45 % | 46 % | 47 % | 20 % |
Smokersa | |||||
- Screening | 65 % | 10 % | 17 % | 17 % | 40 % |
- Control | 79 % | 9 % | 15 % | 15 % | 38 % |
Systolic BP, mmHg ± SD | |||||
- Screening | 143 ± 19 | 133 ± 17 | – | 129 ± 12 | 140 ± 15 |
- Control | 142 ± 17 | 132 ± 16 | – | 131 ± 11 | 141 ± 15 |
Diastolic BP, mmHg ± SD | |||||
- Screening | 86 ± 11 | 80 ± 9 | – | 74 ± 8 | 82 ± 7 |
- Control | 84 ± 10 | 79 ± 8 | – | 74 ± 8 | 81 ± 7 |
LDL-C, mg/dL ± SD | |||||
- Screening | – | 114 ± 32 | – | 86 ± 29 | 125 ± 37 |
- Control | – | 114 ± 33 | – | 88 ± 33 | 119 ± 33 |
HDL-C, mg/dL ± SD | |||||
- Screening | 49 ± 15 | 50 ± 15 | – | 45 ± 14 | 42 ± 11 |
- Control | 46 ± 15 | 49 ± 15 | – | 45 ± 13 | 42 ± 12 |
Triglycerides, mg/dL ± SD or [95 % CI] | |||||
- Screening | 154 ± 105 | 172 ± 118 | – | 144 [99–201] | 163 ± 140 |
- Control | 161 ± 88 | 168 ± 101 | – | 132 [92–198] | 161 ± 96 |
Type 2 diabetes | |||||
- Screening | 100 % | 100 % | 100 % | 88 % | 100 % |
- Control | 100 % | 100 % | 100 % | 88 % | 100 % |
Duration of DM, y ± SD | |||||
- Screening | 11.6 ± 10.6 | 8.2 ± 7.1 | – | 12.3 ± 9.2 | 9.9 ± 6.7 |
- Control | 11.3 ± 10.3 | 8.9 ± 6.9 | – | 13.5 ± 10.7 | 10.0 ± 6.2 |
Insulin | |||||
- Screening | 11 % | 24 % | – | 43 % | 23 % |
- Control | 14 % | 22 % | – | 43 % | 21 % |
HbA1c, % ± SD | |||||
- Screening | 8.6 ± 2.3 | 7.2 ± 1.6 | 8.6 ± 2.2 | 7.4 ± 1.4 | 7.7 ± 1.4 |
- Control | 8.4 ± 1.9 | 7.0 ± 1.5 | 8.7 ± 2.0 | 7.5 ± 1.4 | 7.8 ± 3.1 |
Retinopathy | |||||
- Screening | 56 % | 14 % | – | – | 14 % |
- Control | 59 % | 16 % | – | – | 17 % |
Peripheral vascular disease | |||||
- Screening | – | 9 % | 14 % | – | 5 % |
- Control | – | 9 % | 14 % | – | 7 % |
Statins use (baseline) | |||||
- Screening | 39 % | 37 % | – | 77 % | 49 % |
- Control | 30 % | 41 % | – | 72 % | 44 % |
Aspirin use (baseline) | |||||
- Screening | 13 % | 43 % | – | 43 % | 29 % |
- Control | 17 % | 46 % | – | 41 % | 26 % |
ACE/ARB use (baseline) | |||||
- Screening | 14 % | 37 % | – | – | 62 % |
- Control | 14 % | 41 % | – | – | 65 % |